S. Eckert

发表

Stress-full life events and multiple sclerosis: A population-based incident case-control study.

I. Abdollahpour, M. Mansournia, B. Weinstock-Guttman, 2018, Multiple sclerosis and related disorders.

A Pediatric Case of NMOSD with Positive Seroconversion of AQP4-ab after 5 Years and Subsequent Diagnosis of SLE

B. Weinstock-Guttman, Caila B. Vaughn, S. Eckert, 2017 .

A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis

B. Weinstock-Guttman, D. Jakimovski, S. Eckert, 2022, Multiple sclerosis journal - experimental, translational and clinical.

Late onset multiple sclerosis is associated with more severe ventricle expansion.

D. Ramasamy, M. Dwyer, R. Zivadinov, 2020, Multiple sclerosis and related disorders.

Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment

B. Weinstock-Guttman, D. Jakimovski, S. Eckert, 2021, CNS Drugs.

COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections

B. Weinstock-Guttman, D. Jakimovski, S. Eckert, 2022, Vaccines.

Efficacy and Safety of Ponesimod in Relapsing Multiple Sclerosis: A Systematic Review

S. Eckert, O. Mirmosayyeb, Sara Bagherieh, 2022, Neurology and Clinical Neuroscience.

Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives

M. Dwyer, R. Zivadinov, B. Weinstock-Guttman, 2022, Journal of Neurology.

Considering patient age when treating multiple sclerosis across the adult lifespan

R. Zivadinov, B. Weinstock-Guttman, D. Jakimovski, 2021, Expert review of neurotherapeutics.

Recovery of cognitive function after relapse in multiple sclerosis

R. Benedict, M. Dwyer, R. Zivadinov, 2020, Multiple sclerosis.

A decline in cognitive function should lead to a change in disease-modifying therapy – Yes

R. Benedict, B. Weinstock-Guttman, S. Eckert, 2018, Multiple sclerosis.

Long-term drug treatment in multiple sclerosis: safety success and concerns

R. Zivadinov, B. Weinstock-Guttman, Caila B. Vaughn, 2020, Expert opinion on drug safety.

Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis

D. Ramasamy, R. Zivadinov, B. Weinstock-Guttman, 2020, American Journal of Neuroradiology.

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study

B. Weinstock-Guttman, D. Jakimovski, S. Eckert, 2023, Vaccines.

Infectious exposure, antibiotic use, and multiple sclerosis: A population‐based incident case‐control study

I. Abdollahpour, M. Mansournia, B. Weinstock-Guttman, 2018, Acta neurologica Scandinavica.

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives

B. Weinstock-Guttman, Caila B. Vaughn, D. Jakimovski, 2019, Patient related outcome measures.

PROM_A_168095 373..384

Caila B. Vaughn, D. Jakimovski, S. Eckert, 2019 .

Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis.

D. Ramasamy, M. Dwyer, R. Zivadinov, 2020, Multiple sclerosis and related disorders.

Persistent spinal cord enhancement in longitudinal extensive transverse myelitis associated with α-1-antitrypisn deficiency: a case report

B. Weinstock-Guttman, D. Jakimovski, S. Eckert, 2022, Neuroimmunology Reports.

How to and should we target EBV in MS?

R. Zivadinov, B. Weinstock-Guttman, D. Jakimovski, 2024, Expert review of clinical immunology.

Post-Partum Clinical and Patient-Reported Outcome Changes in Mothers with Multiple Sclerosis: Findings from the NAPPREMS Study

D. Jakimovski, S. Eckert, D. Hojnacki, 2024, Medicina.

Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis.

M. Ramanathan, M. Dwyer, R. Zivadinov, 2024, Multiple sclerosis and related disorders.